Tarsus Pharmaceuticals, Inc. [TARS] - Tarsus Pharmaceuticals / Alkeus Pharmaceuticals merger
Tarsus Pharmaceuticals, Inc. has entered into a definitive merger agreement to acquire Alkeus Pharmaceuticals, Inc. for $270 million in cash and $180 million in stock valued at $61.38 per share, with additional milestone payments of up to $350 million contingent on regulatory approval.
Why this matters
Tarsus Pharmaceuticals, Inc., a Delaware-incorporated company specializing in biological products, has announced a definitive merger agreement to acquire Alkeus Pharmaceuticals, Inc. The acquisition involves a total consideration of $450 million, comprising $270 million in cash and $180 million in stock valued at $61.38 per share. Additionally, there are potential milestone payments of up to $350 million contingent on regulatory approval. The merger is structured to include a Registration Rights Agreement, which will become effective upon closing, ensuring the resale of shares issued to Alkeus equityholders.